Yidu Technology (02158) has spent more than HK$10 million on 6 repurchases since December

The Zhitong Finance App learned that on December 11, Yidu Technology (02158) issued an announcement showing that the company repurchased 535,000 shares at a price of about HK$5 per share on the same day, and the repurchase amount exceeded HK$2.68 million. Since December, the company has repurchased 6 times, with a total repurchase of nearly 2 million shares, with a total amount exceeding HK$10 million.

Regarding the repurchase behavior of listed companies, experts generally believe that the core is that relevant companies judge that their stock prices are at a relatively undervalued level, and that in order to fully exert positive effects, repurchases need to be supported by improvements in fundamentals.

The 2026 interim results report recently disclosed by Yidu Technology just confirms the actual strengthening of its fundamentals. During the reporting period, the company's total revenue reached RMB 358 million, an increase of 8.7% over the previous year; key breakthroughs were achieved in profit quality and operating efficiency. The current business had adjusted EBITDA of about 54 million yuan, double that of the same period last year, and was almost break-even at the accounting reporting level. This milestone was achieved about one year earlier than management's original expectations.

On the basis of a steady increase in performance, industry policy dividends have further brought new development opportunities for Yidu Technology. Recently, the first edition of China's commercial insurance innovative drug catalogue was officially released, injecting strong development impetus into the commercial health insurance and innovative drug industry. Relying on the self-developed “AI medical brain” YiduCore, Yidu Technology can help insurers achieve accurate risk pricing, insurance claims, and medical expenses control while introducing more high-value, cutting-edge innovative drugs.

The company has provided full-process solutions for “Huimin Insurance” projects in Beijing, Shenzhen, Hebei and other provinces and cities, covering core aspects such as intelligent actuarial pricing, claims risk control, system operation and patient services, and has served more than 40 million insured users. “Shenzhen Huimin Insurance”, which is mainly operated by Yidu Technology, has taken the lead in including all 19 innovative drugs in the scope of coverage in the first edition of the commercial insurance innovative drug catalogue in the 2025 guarantee.

In addition to the in-depth layout of the Huimin Insurance field, Yidu Technology also relies on AI medical core capabilities to provide full chain support for pharmaceutical companies from early R&D to commercialization. In the new drug development stage, the company can provide one-stop clinical research services such as project evaluation, patient recruitment, and clinical operation to improve R&D efficiency with data intelligence; in the market entry process, it can also provide key services such as beneficiary/commercial insurance entry strategies, price estimation, and risk sharing mechanism design to help innovative achievements cross the “last mile” and achieve wide accessibility.